Financial Data and Key Metrics Changes - Acadia Pharmaceuticals reported total revenues of $244.3 million for Q1 2025, representing a 19% increase year-over-year [6][29] - R&D expenses increased to $78.3 million from $59.7 million in Q1 2024, driven by higher spending on clinical stage programs [32] - SG&A expenses rose to $126.4 million from $108 million in Q1 2024, primarily due to ongoing consumer activation campaigns for NUPLAZID and expansion of the Debut team [32] Business Line Data and Key Metrics Changes - Debut sales reached $84.6 million in Q1 2025, an 11% increase from the previous year, with a record number of unique patients receiving shipments [7][29] - NUPLAZID generated $159.7 million in revenue for the quarter, up 23% year-over-year, with 6% of this growth attributed to volume [7][31] Market Data and Key Metrics Changes - The number of unique patients receiving Debut shipments was 954, marking an all-time high for the brand [7][11] - NUPLAZID's gross price increased by over 2% year-over-year, with a gross-to-net adjustment of 24.1% for the quarter [31] Company Strategy and Development Direction - Acadia is focused on accelerating the commercial trajectory of Debut and capitalizing on the momentum of NUPLAZID while expanding its global presence [35] - The company plans to host its first R&D Day to provide insights into its development strategy and pipeline innovations [9][35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of Debut's growth and reiterated full-year sales guidance for both Debut and NUPLAZID [7][35] - The timeline for the COMPASS PWS Phase III study results is now expected by the end of 2025, indicating progress in pipeline development [9][35] Other Important Information - Acadia anticipates EMA approval for Debut in Q1 2026, with a substantial market opportunity in Europe for Rett syndrome patients [14][28] - The company has received orphan drug designation for trofinetide in Japan, which may lead to priority review [28] Q&A Session Summary Question: What does good 101 data look like and how does it relate to FDA discussions? - Management indicated that statistically significant results demonstrating a clinically meaningful impact on hyperphagia would be considered good data [40] Question: How should we model a European price for Debut? - Management expressed confidence in obtaining a strong EU price that reflects the value provided to patients in the Rett community [41] Question: What are the key growth drivers for NUPLAZID and Debut from Q1 to Q2? - Management highlighted patient demand and the impact of expanded customer models as key growth drivers for both brands [44][46] Question: What are the biggest risks to the approval process for trofinetide in the EU? - Management stated confidence in the EMA approval process, noting that they are on track with the regulatory timeline [80] Question: How does Acadia view its positioning against Celeno's product for Prader Willi? - Management believes there is room for multiple therapies in the Prader Willi space, emphasizing the complexity of patient needs [95]

Financial Data and Key Metrics Changes - Total revenues for Q1 2025 reached $114.8 million, a year-over-year increase of $32.9 million, translating to approximately 40% growth [11][20] - Adjusted for voluntary product withdrawals, revenues would have been $118.6 million, representing approximately 45% year-over-year growth [11][20] - Adjusted net income grew by 87% year-over-year to $33.3 million, while adjusted EBITDA increased by 81% to $47.9 million [12][22] Business Line Data and Key Metrics Changes - The increase in total revenue is primarily attributed to higher sales of Ascentive, reflecting increased acceptance and utilization by physicians, payers, and patients [20] - Gross profit for Q1 2025 was $61.1 million, with a gross margin of 53.2%, up from 47.8% in Q1 2024, driven by a favorable mix of higher margin immunoglobulin sales [21] Market Data and Key Metrics Changes - The company has seen robust demand for its commercial products, particularly Ascentive and BIVIGAM, with new patient starts continuing to grow [13][14] - Cash on hand and accounts receivable grew to a combined $171 million at the end of Q1 2025, providing a strong buffer against market volatility [14][24] Company Strategy and Development Direction - The company is focused on advancing its R&D platform and optimizing production capabilities, particularly with the recent FDA approval of the yield enhancement production process, which is expected to increase bulk immunoglobulin output by 20% [8][12] - A stock repurchase program has been authorized, allowing the company to buy back up to $500 million of its common stock, reflecting confidence in its financial position and future growth [15][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve sustainable revenue and earnings growth, driven by a strong balance sheet and capital flexibility [14][26] - The company anticipates significant growth in cash flow and plans to utilize this for debt reduction, funding R&D, and stock repurchases [43][44] Other Important Information - The company has successfully navigated recent geopolitical and trade challenges due to its U.S.-based supply chain and domestic operations [7][8] - The FDA's approval of the yield enhancement process is seen as a pivotal achievement, validating the company's R&D efforts and enhancing its market position [9][10] Q&A Session Summary Question: Guidance increase and yield enhancement process - Management confirmed that three conformance lots were manufactured to secure FDA clearance, and they are conservatively excluding these from 2025 guidance [31][33] Question: Demand generation and backlog for Ascentive - Management indicated that operational expenses are expected to normalize, and demand indicators for all products are strong, supporting revenue growth [41][42] Question: Supply agreements and plasma collection - Management reported that nearly all new centers are contributing to plasma supply, exceeding initial forecasts and supporting increased guidance [49][51] Question: Health economic outcome data for Ascentive - Management is on track to publish health economic outcome data by year-end, which is expected to resonate with payers and support access to the drug [63][64] Question: Voluntary product withdrawals - Management clarified that the withdrawals were due to known adverse events and are considered a one-time occurrence, with no expected ongoing impacts [66][70] Question: Intellectual property extension - Management expressed confidence in extending the IP for Ascentive and highlighted the robust patent protection in place [72][75]

Summary of Conference Call Company Overview - The conference call was led by Andrew Yoon, director of finance and investor relations, discussing sales results for the retail month of April, comparing it to the same period last year [1] Key Financial Metrics - Net sales for April reached $21.18 billion, marking a 7% increase from $19.8 billion in the previous year [2] - The month had one less shopping day compared to last year due to the shift in Easter, negatively impacting total and comparable sales by approximately 1.5% to 2% [2] Comparable Sales Performance - Reported comparable sales for April were as follows: - US: 5.2% - Canada: 1.5% - Other International: 3.2% - Total Company: 4.4% - E-commerce: 12.6% [3] - Comparable sales excluding impacts from gasoline prices and foreign exchange were: - Total Company: 6.7% - E-commerce: 13% [3] - Comp traffic increased by 4.2% worldwide and 5% in the US [3] Impact of External Factors - Foreign currency fluctuations negatively impacted total and comparable sales: - Canada: -1.6% - Other International: -2.5% - Total Company: -0.6% [3] - Gas price deflation negatively impacted total reported comparable sales by approximately -1.7%, with the average worldwide selling price per gallon down about 13.4% year-over-year [4] Regional Performance - Strongest comparable sales in the US were observed in the Midwest, Northeast, and Southeast regions [5] - Internationally, the best results were seen in Mexico, Korea, and Taiwan [5] Merchandise Highlights - Foods and sundries showed positive high single-digit growth [5] - Better performing departments included: - Fresh foods: high single digits - Meat and bakery: strong performance - Non-foods: mid to high single digits, with jewelry, majors, and home furnishings performing well [6] - Ancillary business sales were down mid to high single digits, while pharmacy, optical, and food court were the top performers [7] Future Outlook - The May reporting period will cover the four weeks beginning May 5 and ending June 1, compared to the same period last year [7]

| . | | --- | | and the country of the same of the county of the county of the county of | | GREASURED FOR THE OF OF EN INFORMATION OF IN AT IN OIL OF CHILDIN . . . | | . . ADDRESSES OF IS IN 30 SEPRANAGEMENT OF IN TO SUSPER | | . | | and the control of the control of the control of the first of the firs | | . | Q1 2025 Financial Results May 7, 2025 Safe Harbor Statement Information, statements and projections contained in these presentation slides and related conference call concerning Fortinet's business ...

MAY 7, 2025 First Quarter 2025 Earnings Call Call Agenda | Welcome | Al Kildani Senior Vice President, Investor Relations and Corporate Communications | | --- | --- | | CEO Opening Remarks | Catherine Owen Adams Chief Executive Officer | | Commercial Update | Tom Garner Executive Vice President, Chief Commercial Officer | | R&D Update | Elizabeth H.Z. Thompson Executive Vice President, Head of Research and Development | | Financial Update | Mark Schneyer Executive Vice President, Chief Financial Officer | | ...

INVESTOR PRESENTATION Q1'25 Results May 7, 2025 DISCLAIMERS First Quarter 2025 This presentation may contain forward-looking statements including, but not limited to, statements regarding MercadoLibre, Inc.'s expectations, objectives and progress against strategic priorities; initiatives and strategies related to our products and services; business and market outlook, opportunities, strategies and trends; impacts of foreign exchange; the potential impact of the uncertain macroeconomic and geopolitical envir ...

HIGHLIGHTS Q1-25 EARNINGS PRESENTATION MAY 7, 2025 © 2025 ACV Auctions, Inc. FORWARD LOOKING STATEMENTS Statements in this presentation regarding future performance and future expectations, beliefs, goals, plans or prospects include forward looking statements for purposes of federal and state securities laws, including statements regarding ACV's avenues for long term growth and total addressable market expansion, our financial guidance for the second quarter and full year of 2025, and operational and produc ...

Summary of Adicet Bio (ACET) Conference Call Company Overview - Adicet Bio is a leader in gamma delta CAR T cell therapies, which have several advantages over traditional therapies, including being off-the-shelf, better safety profiles, and effective tissue distribution [3][4][5][6][7]. Key Advantages of Gamma Delta CAR T Cells - **Off-the-Shelf Availability**: Gamma delta CAR T cells can be administered without prior patient-specific modifications, reducing preparation time [3]. - **Safety Profile**: These cells are associated with lower rates of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) compared to alpha beta T cells [4]. - **Tissue Distribution**: Gamma delta T cells effectively localize to tissues, which is beneficial for treating autoimmune diseases and solid tumors [5][6]. - **Innate Antitumor Activity**: They can target tumor cells even if they do not express the specific target, enhancing their therapeutic potential [7]. Clinical Programs and Data - Adicet Bio is currently running two clinical programs and has two preclinical programs in development [8]. - In clinical trials for diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), the complete response (CR) rates were comparable to autologous therapies, with a notable safety advantage [11][12]. - The company is focusing on autoimmune diseases, particularly lupus nephritis (LN) and systemic lupus erythematosus (SLE), with plans to expand to other conditions like systemic sclerosis and ANCA vasculitis [19][21]. Market Potential and Unmet Needs - The market for autoimmune diseases is significant, with high unmet medical needs, particularly in conditions like lupus nephritis, where patients face severe long-term health risks [25]. - The company aims to provide a one-time therapy that could lead to complete responses, reducing the need for ongoing immunosuppressants [25]. Data Expectations and Patient Selection - Investors are looking for data from at least six patients with three months of follow-up to assess efficacy [27]. - The ideal patient profile includes younger individuals with recent diagnoses and minimal existing tissue damage [31]. Competitive Landscape - The cell therapy space is competitive, with many companies pivoting from oncology to autoimmune diseases based on promising academic data [33]. - Adicet Bio differentiates itself by offering off-the-shelf therapies that do not require leukapheresis or personalized manufacturing, which can complicate treatment [36][39]. Future Developments - The company is also exploring renal cell carcinoma (RCC) as a new target, leveraging its unique advantages in tissue targeting and safety [44][46]. - Data from RCC trials is expected in the second half of the year, with a focus on achieving better outcomes than existing therapies [49]. Financial Position - Adicet Bio has approximately $150 million in cash, which is expected to fund operations into the second half of the following year [52]. - The company is open to business development opportunities to enhance its pipeline and financial stability [52]. Regulatory Environment - Interactions with regulatory agencies have been positive, with a collaborative approach noted in discussions about innovative therapies [53][54]. - The company believes that therapies demonstrating significant patient benefits will receive favorable attention from regulators [54]. Conclusion - Adicet Bio is positioned to make significant advancements in both autoimmune and oncology sectors with its gamma delta CAR T cell therapies, addressing critical unmet needs while navigating a competitive landscape and regulatory challenges [56].

Financial Data and Key Metrics Changes - For Q1 2025, the company reported GAAP net income of approximately $9.3 million or $0.17 per common share, with distributable earnings of approximately $7.2 million or $0.13 per common share [10] - The company collected $3,700,000 in repayments across nine loans, double the amount from the previous quarter, marking the highest repayments as a percentage of outstanding principal balance in the company's history [5][11] - Outstanding borrowings were reduced by $228 million to $946 million, resulting in a net debt to equity ratio of 1.2 times, down from 1.9 times at the end of Q1 2024 [5][11] Business Line Data and Key Metrics Changes - The company reduced its office loan portfolio by 25% since Q1 2024, decreasing the total outstanding balance to $585 million [6] - There were no new migrations to risk-rated four or five loans in Q1 2025, indicating improved credit quality across the portfolio [10][11] Market Data and Key Metrics Changes - The total CECL reserve declined to $140 million as of Q1 2025, a decrease of approximately $5 million from the previous quarter, representing about 9.9% of the total outstanding principal balance of loans held for investment [14] Company Strategy and Development Direction - The company aims to demonstrate book value and is positioned to selectively originate new loans, repurchase common shares, repay debt, and fund strategic initiatives [8][9] - The acquisition of GCP has expanded the company's real estate team, enhancing its ability to execute its strategy and deliver shareholder returns [18][45] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the uncertainty in the economic environment but expressed confidence in the company's capabilities and balance sheet strength to build shareholder value [18][19] - The company is being selective in new lending opportunities, waiting for market stabilization before expanding its loan portfolio [32][34] Other Important Information - The Board declared a regular cash dividend of $0.15 per common share for Q2 2025, with an annualized dividend yield of over 14% based on the current stock price [15] Q&A Session Summary Question: Update on the Chicago office loan - Management indicated that while the asset has positive leasing momentum, market dynamics have negatively impacted its valuation, maintaining a conservative reserve [22][23] Question: Anticipated cadence for resolving non-performing loans - Management noted that predicting the cadence of resolutions is challenging due to market volatility, but they are prepared to accelerate resolutions when appropriate [25][26] Question: Plans for loan portfolio growth - Management confirmed they are being patient and selective regarding new investments, with a focus on evaluating opportunities as the market stabilizes [30][32] Question: Buyback authorization and capital allocation - The company has a $50 million buyback authorization in place and is evaluating the use of additional capital for stock repurchases [37] Question: Update on the Life Science Boston project - Management acknowledged challenges in the market but indicated ongoing discussions with the sponsor and a cautious approach to reserves [40][41] Question: Clarification on strategic initiatives - Management clarified that strategic initiatives include evaluating share buybacks and new investments, particularly in light of the GCP acquisition [42][45]

Financial Data and Key Metrics Changes - In Q1 2025, ProFrac reported revenue of $600 million, a 32% increase from $455 million in Q4 2024, while adjusted EBITDA rose 83% to $130 million from $71 million in the previous quarter [5][29][30] - The adjusted EBITDA margin improved to 22% in Q1 from 16% in Q4 [30] Business Line Data and Key Metrics Changes - The Stimulation Services segment generated $525 million in revenue in Q1, up from $384 million in Q4, with adjusted EBITDA increasing to $105 million from $54 million [30] - The Proppant Production segment saw revenues rise to $67 million in Q1 from $47 million in Q4, driven by a 53% increase in sales volumes [31] - The Manufacturing segment's revenue increased by 6% sequentially to $66 million, with adjusted EBITDA improving to approximately $4 million [33] Market Data and Key Metrics Changes - The company experienced a significant improvement in active fleet count, with six fleets returning to service early in Q1, particularly in the Eagle Ford and Permian regions [21] - Demand for next-gen natural gas burning equipment remained resilient compared to diesel assets [21] Company Strategy and Development Direction - ProFrac is focused on leveraging its in-house R&D, manufacturing, and maintenance capabilities to enhance operational efficiency and customer service [5][19] - The company completed a strategic transaction with Flotek, enhancing its gas quality assurance and asset integrity solutions, which is expected to drive future growth [10][19] - ProFrac is optimistic about the potential in the Haynesville region, particularly for natural gas-directed activity [17][26] Management's Comments on Operating Environment and Future Outlook - Management noted that economic uncertainty from tariffs and OPEC's production increase has impacted commodity prices and spending outlook [14][15] - Operators are expected to reduce activity in Q2 relative to Q1, but some maintain flexibility to resume operations quickly when conditions improve [15][16] - The natural gas market is showing resilience, with potential for increased activity in the second half of 2025 [17][19] Other Important Information - The company identified potential CapEx reductions of $70 million to $100 million to align with evolving market conditions [28] - Total cash and cash equivalents as of March 31, 2025, were approximately $16 million, with total liquidity at about $76 million [34] Q&A Session Summary Question: Can you provide more specific guidance on the second quarter outlook? - Management acknowledged a pullback in Q2 but noted uncertainty on the degree, emphasizing customer-specific evaluations [39][41] Question: What is the capacity of your electric frac assets? - Most electric fleets are on long-term contracts and remain fully utilized, with seven electric frac fleets deployed [43][45] Question: Can you comment on the performance of specific fleets? - Record-breaking pump times were noted across the fleet, attributed to operational excellence and asset management [51][53] Question: How do you expect Q4 seasonality to impact performance? - Management expects a muted seasonal slowdown in Q4 compared to previous years, with strong gas market fundamentals [57][59] Question: What are the pricing dynamics in the Haynesville versus West Texas? - The Haynesville market is expected to provide significant opportunities, with a focus on balancing volumes and pricing [67][68]